Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria.
作者信息
Fahim Shahariar Mohammed, Makam Anil N, Suh Kangho, Carlson Josh J, Richardson Marina, Herce-Hagiwara Belen, Dickerson Ronald, Pearson Steven D, Agboola Foluso
机构信息
Institute for Clinical and Economic Review, Boston, MA.
Department of Medicine, University of California San Francisco.
出版信息
J Manag Care Spec Pharm. 2024 Jun;30(6):618-623. doi: 10.18553/jmcp.2024.30.6.618.
Abstract
摘要
相似文献
1
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria.
J Manag Care Spec Pharm. 2024 Jun;30(6):618-623. doi: 10.18553/jmcp.2024.30.6.618.
2
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Lancet Haematol. 2021 May;8(5):e344-e354. doi: 10.1016/S2352-3026(21)00028-4. Epub 2021 Mar 23.
3
Iptacopan (Fabhalta) for paroxysmal nocturnal hemoglobinuria.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e171-e173. doi: 10.58347/tml.2024.1712e.
4
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
Blood Rev. 2024 Jul;66:101210. doi: 10.1016/j.blre.2024.101210. Epub 2024 May 25.
5
The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria.
Ann Hematol. 2022 Nov;101(11):2537-2539. doi: 10.1007/s00277-022-04933-5. Epub 2022 Aug 15.
6
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply.
N Engl J Med. 2024 Jun 6;390(21):2033-2034. doi: 10.1056/NEJMc2404445.
7
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med. 2024 Jun 6;390(21):2033. doi: 10.1056/NEJMc2404445.
8
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med. 2024 Jun 6;390(21):2032-2033. doi: 10.1056/NEJMc2404445.
9
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med. 2024 Mar 14;390(11):994-1008. doi: 10.1056/NEJMoa2308695.
10
Danicopan: First Approval.
Drugs. 2024 May;84(5):613-618. doi: 10.1007/s40265-024-02023-6. Epub 2024 Mar 26.
引用本文的文献
1
Crovalimab: A Novel Approach in the Management of Paroxysmal Nocturnal Hemoglobinuria.
Health Sci Rep. 2025 Jul 13;8(7):e70986. doi: 10.1002/hsr2.70986. eCollection 2025 Jul.
2
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024.
Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398(5):5077-5099. doi: 10.1007/s00210-025-04020-2. Epub 2025 Mar 31.
3
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria.
Blood. 2025 Jan 2;145(1):127-140. doi: 10.1182/blood.2024025176.
本文引用的文献
1
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lancet Haematol. 2023 Dec;10(12):e955-e965. doi: 10.1016/S2352-3026(23)00315-0.
2
Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition.
N Engl J Med. 2022 Jul 14;387(2):160-166. doi: 10.1056/NEJMra2201664.
3
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med. 2021 Mar 18;384(11):1028-1037. doi: 10.1056/NEJMoa2029073.
4
How I treat paroxysmal nocturnal hemoglobinuria.
Blood. 2021 Mar 11;137(10):1304-1309. doi: 10.1182/blood.2019003812.
5
Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria.
Hematol Transfus Cell Ther. 2021 Jul-Sep;43(3):341-348. doi: 10.1016/j.htct.2020.06.006. Epub 2020 Jul 6.
6
Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry.
Ann Hematol. 2020 Jul;99(7):1505-1514. doi: 10.1007/s00277-020-04052-z. Epub 2020 May 10.
7
Pesg PNH diagnosis, follow-up and treatment guidelines.
Am J Blood Res. 2016 Aug 5;6(2):19-27. eCollection 2016.
8
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
Br J Haematol. 2013 Jul;162(1):62-73. doi: 10.1111/bjh.12347. Epub 2013 Apr 25.
9
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.
Blood. 2011 Jun 23;117(25):6786-92. doi: 10.1182/blood-2011-02-333997. Epub 2011 Apr 1.
10
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
Blood. 2005 Dec 1;106(12):3699-709. doi: 10.1182/blood-2005-04-1717. Epub 2005 Jul 28.
Zotero 插件